M Boeckh

Summary

Affiliation: Fred Hutchinson Cancer Research Center
Country: USA

Publications

  1. ncbi request reprint Prevention of VZV infection in immunosuppressed patients using antiviral agents
    Michael Boeckh
    Fred Hutchinson Cancer Research Center, Program in Infectious Diseases, University of Washington, Seattle, WA 98109, USA
    Herpes 13:60-5. 2006
  2. pmc Cytopenias after day 28 in allogeneic hematopoietic cell transplantation: impact of recipient/donor factors, transplant conditions and myelotoxic drugs
    Hirohisa Nakamae
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Haematologica 96:1838-45. 2011
  3. ncbi request reprint Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity
    Michael Boeckh
    Program in Infectious Diseases Immunology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Blood 101:407-14. 2003
  4. pmc Impact of corticosteroid treatment and antiviral therapy on clinical outcomes in hematopoietic cell transplant patients infected with influenza virus
    Alexandre A Boudreault
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 17:979-86. 2011
  5. ncbi request reprint Immunosuppressive effects of beta-herpesviruses
    Michael Boeckh
    Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA
    Herpes 10:12-6. 2003
  6. pmc Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR
    Michael Boeckh
    Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, Washington 98109 1024, USA
    J Clin Microbiol 42:1142-8. 2004
  7. ncbi request reprint The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy
    Michael Boeckh
    Program in Ifectious Diseases, Fred Hutcinson Cancer Research Center and University of Washington, Settle, 98105, USA
    Blood 103:2003-8. 2004
  8. pmc How we treat cytomegalovirus in hematopoietic cell transplant recipients
    Michael Boeckh
    Vaccine and Infectious Disease Institute and Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 113:5711-9. 2009
  9. pmc The challenge of respiratory virus infections in hematopoietic cell transplant recipients
    Michael Boeckh
    Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, School of Medicine, University of Washington, Seattle, WA, USA
    Br J Haematol 143:455-67. 2008
  10. ncbi request reprint Recent advances in the prevention of CMV infection and disease after hematopoietic stem cell transplantation
    Michael Boeckh
    Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA 98109, USA
    Pediatr Transplant 8:19-27. 2004

Research Grants

Detail Information

Publications88

  1. ncbi request reprint Prevention of VZV infection in immunosuppressed patients using antiviral agents
    Michael Boeckh
    Fred Hutchinson Cancer Research Center, Program in Infectious Diseases, University of Washington, Seattle, WA 98109, USA
    Herpes 13:60-5. 2006
    ..Current evidence on the use of antiviral agents in the prevention of reactivation disease and management of exposure to VZV is discussed...
  2. pmc Cytopenias after day 28 in allogeneic hematopoietic cell transplantation: impact of recipient/donor factors, transplant conditions and myelotoxic drugs
    Hirohisa Nakamae
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Haematologica 96:1838-45. 2011
    ..Etiologies include myelotoxic agents, viral infections, and possibly transplant-related factors such as the intensity of the conditioning regimen and the source of stem cells...
  3. ncbi request reprint Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity
    Michael Boeckh
    Program in Infectious Diseases Immunology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Blood 101:407-14. 2003
    ..Prevention strategies should be targeted at patients in whom CMV reactivated during the first 3 months and those with poor CMV-specific immunity or low CD4 counts...
  4. pmc Impact of corticosteroid treatment and antiviral therapy on clinical outcomes in hematopoietic cell transplant patients infected with influenza virus
    Alexandre A Boudreault
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 17:979-86. 2011
    ..Antiviral therapy initiated during the URI phase reduced the risk of LRD and hypoxemia...
  5. ncbi request reprint Immunosuppressive effects of beta-herpesviruses
    Michael Boeckh
    Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA
    Herpes 10:12-6. 2003
    ..More trials are needed to evaluate whether the effects seen in observational studies are truly related...
  6. pmc Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR
    Michael Boeckh
    Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, Washington 98109 1024, USA
    J Clin Microbiol 42:1142-8. 2004
    ..Thus, primer optimization and improved DNA extraction techniques resulted in a plasma-based PCR assay that is significantly more sensitive than pp65 antigenemia and blood cultures for detection of CMV in blood specimens...
  7. ncbi request reprint The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy
    Michael Boeckh
    Program in Ifectious Diseases, Fred Hutcinson Cancer Research Center and University of Washington, Settle, 98105, USA
    Blood 103:2003-8. 2004
    ..Prevention strategies may require targeting both the direct and indirect effects of CMV infection by immunologic or antiviral drug strategies...
  8. pmc How we treat cytomegalovirus in hematopoietic cell transplant recipients
    Michael Boeckh
    Vaccine and Infectious Disease Institute and Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 113:5711-9. 2009
    ....
  9. pmc The challenge of respiratory virus infections in hematopoietic cell transplant recipients
    Michael Boeckh
    Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, School of Medicine, University of Washington, Seattle, WA, USA
    Br J Haematol 143:455-67. 2008
    ..This article reviews the spectrum of pathogens, epidemiology, risk factors and clinical manifestations of infection, as well as recent advances in diagnostic and clinical management...
  10. ncbi request reprint Recent advances in the prevention of CMV infection and disease after hematopoietic stem cell transplantation
    Michael Boeckh
    Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA 98109, USA
    Pediatr Transplant 8:19-27. 2004
    ..The development of new drugs and immunologic strategies (adoptive transfer of CMV-specific T-cells and donor/recipient vaccination strategies) are important goals for the elimination of the negative impact of CMV in the HCT setting...
  11. ncbi request reprint Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients
    Michael Boeckh
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Clin Infect Dis 44:245-9. 2007
    ..Respiratory syncytial virus infection of the upper airways may progress to fatal pneumonia in hematopoietic cell transplant recipients. The safety and efficacy of aerosolized ribavirin in preventing disease progression is unknown...
  12. ncbi request reprint Rising CMV PP65 antigenemia and DNA levels during preemptive antiviral therapy
    Michael Boeckh
    Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, and Department of Medicine, University of Washington, Seattle, Washington, USA
    Haematologica 90:439. 2005
  13. pmc Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation--a randomized double-blind placebo-controlled study
    Michael Boeckh
    Fred Hutchinson Cancer Research Center, Program in Infectious Diseases, 1100 Fairview Ave N, Seattle, WA 98109, USA
    Blood 107:1800-5. 2006
    ..Periods of prophylaxis longer than 12 months may be beneficial for those hematopoietic cell transplant recipients on continued immune suppression...
  14. ncbi request reprint Emerging viral infections after hematopoietic cell transplantation
    Michael Boeckh
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Pediatr Transplant 9:48-54. 2005
    ..HHV-6 has been strongly associated with encephalitis and delayed platelet engraftment. Prospective studies are needed to further examine epidemiology, disease associations, and management strategies for these viruses...
  15. ncbi request reprint Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation
    M Boeckh
    Fred Hutchinson Cancer Research Center and University of Washington, Seattle 98109, USA
    Biol Blood Marrow Transplant 7:343-51. 2001
    ..Thus, there is no evidence that MSL-109 is beneficial in CMV-seropositive HSCT recipients...
  16. pmc Quantitation of cytomegalovirus: methodologic aspects and clinical applications
    M Boeckh
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Clin Microbiol Rev 11:533-54. 1998
    ..Due to the widespread use of quantitative CMV detection techniques to direct and monitor antiviral treatment, there is a great need for an assessment of the reproducibility of test results and better standardization of the assays...
  17. doi request reprint Complications, diagnosis, management, and prevention of CMV infections: current and future
    Michael Boeckh
    Vaccine and Infectious Disease and Clinical Research Divisions, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 4417, USA
    Hematology Am Soc Hematol Educ Program 2011:305-9. 2011
    ..This article reviews current aspects of CMV diagnosis, prevention, and treatment in HCT recipients and defines areas of unmet medical need...
  18. ncbi request reprint Effect of high-dose acyclovir on survival in allogeneic marrow transplant recipients who received ganciclovir at engraftment or for cytomegalovirus pp65 antigenemia
    M Boeckh
    Fred Hutchinson Cancer Research Center, Seattle, Program in Infectious Diseases, 98109 4417, USA
    J Infect Dis 178:1153-7. 1998
    ..Thus, high-dose acyclovir does not appear to improve survival when ganciclovir is given either at engraftment or for CMV pp65 antigenemia...
  19. ncbi request reprint Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants
    M Boeckh
    Program in Infectious Diseases, Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA 98109, USA
    J Infect Dis 184:350-4. 2001
    ..Thus, palivizumab appears to be safe and well tolerated in HSCT recipients...
  20. ncbi request reprint Current antiviral strategies for controlling cytomegalovirus in hematopoietic stem cell transplant recipients: prevention and therapy
    M Boeckh
    Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, Washington 98109 4417, USA
    Transpl Infect Dis 1:165-78. 1999
    ..Owing to continued clinical significance of CMV in the HSCT setting, new and more effective anti-CMV drugs with improved pharmacokinetic properties are urgently needed...
  21. pmc Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation
    Hirohisa Nakamae
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 15:694-703. 2009
    ..Therefore, CMV prevention strategies in NM-HCT recipients should be similar to those used in M-HCT recipients...
  22. pmc Risk factors for late-onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney transplant recipients who receive antiviral prophylaxis
    A A Boudreault
    Department of Medicine, University of Washington, Seattle, Washington, USA
    Transpl Infect Dis 13:244-9. 2011
    ..Cytomegalovirus (CMV) disease occurs frequently after cessation of antiviral prophylaxis in CMV-seronegative kidney transplant recipients from seropositive donors (D+R-), and the risk factors are incompletely defined...
  23. ncbi request reprint Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation
    J Storek
    Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA, USA
    Blood 97:3380-9. 2001
    ..008). In conclusion, blood stem cell recipients have higher lymphocyte-subset counts and this appears to result in fewer infections. (Blood. 2001;97:3380-3389)..
  24. ncbi request reprint Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial
    K A Marr
    Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA 98109 1024, USA
    Blood 96:2055-61. 2000
    ....
  25. ncbi request reprint Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants
    A P Limaye
    Department of Laboratory Medicine, University of Washington, Seattle 98195 7110, USA
    Lancet 356:645-9. 2000
    ..We retrospectively assessed the occurrence of ganciclovir-resistant cytomegalovirus disease among transplant recipients who had received oral ganciclovir prophylaxis and highly potent immunosuppression...
  26. ncbi request reprint Cytomegalovirus (CMV) DNA load in plasma for the diagnosis of CMV disease before engraftment in hematopoietic stem-cell transplant recipients
    A P Limaye
    Departments of Laboratory Medicine and Medicine, University of Washington, Seattle, WA 98195 7110, USA
    J Infect Dis 183:377-82. 2001
    ..5x107] vs. <50 [range, <50-350] CMV DNA copies/mL plasma, respectively; P<.001). Quantitative PCR for CMV DNA in plasma appears to be useful for the identification of HSCT recipients at risk for CMV disease before engraftment...
  27. ncbi request reprint Impact of unrelated donor status on the incidence and outcome of cytomegalovirus infections after non-myeloablative allogeneic stem cell transplantation
    Christian Junghanss
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Br J Haematol 123:662-70. 2003
    ....
  28. ncbi request reprint Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study
    Christian Junghanss
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA 98109 1024, USA
    Blood 99:1978-85. 2002
    ..Therefore, nonmyeloablative HSCT patients should receive CMV surveillance beyond day 100 and pre-emptive ganciclovir treatment similar to that of myeloablative HSCT patients...
  29. pmc BK DNA viral load in plasma: evidence for an association with hemorrhagic cystitis in allogeneic hematopoietic cell transplant recipients
    Veronique Erard
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Program in Infectious Diseases, 1100 Fairview Ave North D3 100, PO Box 19024, Seattle, WA 98109 1024, USA
    Blood 106:1130-2. 2005
    ..BK virus seems to play a role in the development of HC and quantitative detection of BK DNA in plasma appears to be a marker of BK virus disease in HCT recipients...
  30. ncbi request reprint Community-acquired respiratory syncytial virus and parainfluenza virus infections after hematopoietic stem cell transplantation: the Fred Hutchinson Cancer Research Center experience
    W G Nichols
    Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Biol Blood Marrow Transplant 7:11S-15S. 2001
    ..Two controlled clinical trials of ribavirin therapy for RSV infection in HSCT recipients are in progress...
  31. ncbi request reprint Granulocyte transfusion therapy for infections in candidates and recipients of HPC transplantation: a comparative analysis of feasibility and outcome for community donors versus related donors
    Kai Hubel
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Transfusion 42:1414-21. 2002
    ....
  32. ncbi request reprint De novo chronic graft-versus-host disease in marrow graft recipients given methotrexate and cyclosporine: risk factors and survival
    J L Wagner
    Clinical Research, Department of Medicine, University of Washington, Seattle, USA
    Biol Blood Marrow Transplant 6:633-9. 2000
    ....
  33. ncbi request reprint Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease
    Veronique Erard
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    J Infect Dis 196:266-70. 2007
    ..2% [95% CI, 0%-0.8%]; P=.006), and in 0 patients in cohort 3 (cohort 2 vs. cohort 3, P=.3). Long-term use of suppressive prophylactic ACV appears to prevent the emergence of drug-resistant HSV disease in HCT...
  34. ncbi request reprint Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality
    Arlo Upton
    Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA 98109, USA
    Clin Infect Dis 44:531-40. 2007
    ..The aim of this study was to determine the probability of survival and prognostic factors associated with outcomes over a long period of time...
  35. pmc Respiratory virus infection among hematopoietic cell transplant recipients: evidence for asymptomatic parainfluenza virus infection
    Angela J Peck
    Department of Pediatrics, Children s Hospital and Regional Medical Center and University of Washington, Seattle, WA, USA
    Blood 110:1681-8. 2007
    ..004). Subclinical infection with PIV may help explain why infection-control programs that emphasize symptoms are effective against RSV and influenza but often not against PIV...
  36. ncbi request reprint Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning
    Takahiro Fukuda
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 102:827-33. 2003
    ..More effective strategies are needed to prevent invasive mold infections, which currently account for a notable proportion of nonrelapse mortality after nonmyeloablative allogeneic HCT...
  37. ncbi request reprint Brief communication: fatal human metapneumovirus infection in stem-cell transplant recipients
    Janet A Englund
    Children s Hospital and Regional Medical Center, University of Washington, and Fred Hutchinson Cancer Research Center, Seattle, Washington 98105, USA
    Ann Intern Med 144:344-9. 2006
    ..Human metapneumovirus (hMPV), a recently discovered respiratory virus, is associated with clinical disease in young and elderly persons...
  38. ncbi request reprint Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome
    W G Nichols
    Fred Hutchinson Cancer Research Center, University of Washington, 1100 Fairview Ave N, Seattle, WA 98109-4417, USA
    Blood 98:573-8. 2001
    ..Currently available antiviral therapy appears to be inadequate in reducing viral shedding or mortality once pneumonia is established. (Blood. 2001;98:573-578)..
  39. ncbi request reprint One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation
    Veronique Erard
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 110:3071-7. 2007
    ..To effectively prevent VZV disease in long-term hematopoietic cell transplantation survivors, additional approaches such as vaccination will probably be required...
  40. ncbi request reprint Airflow decline after myeloablative allogeneic hematopoietic cell transplantation: the role of community respiratory viruses
    Veronique Erard
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109 1024, USA
    J Infect Dis 193:1619-25. 2006
    ..Thus, community respiratory virus-associated airflow decline seems to be specific to viral species and infection localization...
  41. ncbi request reprint Community respiratory virus infections in immunocompromised patients: hematopoietic stem cell and solid organ transplant recipients, and individuals with human immunodeficiency virus infection
    Yae Jean Kim
    Division of Infectious Diseases, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Semin Respir Crit Care Med 28:222-42. 2007
    ..Clinicians should appreciate the potential for the development of antiviral resistance to influenza antivirals in immunocompromised patients...
  42. pmc Reduced mortality after allogeneic hematopoietic-cell transplantation
    Ted A Gooley
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    N Engl J Med 363:2091-101. 2010
    ..Over the past decade, advances have been made in the care of patients undergoing transplantation. We conducted a study to determine whether these advances have improved the outcomes of transplantation...
  43. ncbi request reprint Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies
    Michael Boeckh
    University of Washington, Seattle, WA 81009, USA
    Biol Blood Marrow Transplant 9:543-58. 2003
    ....
  44. ncbi request reprint Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation
    Morgan Hakki
    Fred Hutchinson Cancer Research Center, and the University of Washington, Seattle, USA
    Blood 102:3060-7. 2003
    ..Subclinical CMV reactivation while on ganciclovir appears to be a potent stimulator of T-cell function. These findings have implications for vaccination and adoptive-immunotherapy strategies in this population...
  45. doi request reprint Cytomegalovirus infection and ganciclovir resistance caused by UL97 mutations in pediatric transplant recipients
    Y J Kim
    Fred Hutchinson Cancer Research Center, Seattle, Washington, USA Seattle Children s Hospital, Seattle, Washington, USA Sungkyungkwan University, School of Medicine, Samsung Medical Center, Seoul, Korea
    Transpl Infect Dis 14:611-7. 2012
    ..Cytomegalovirus (CMV) infection may cause serious disease after hematopoietic cell transplantation (HCT) and solid organ transplantation (SOT), but few reports describe ganciclovir (GCV) resistance in pediatric patients...
  46. ncbi request reprint Quantitative real-time polymerase chain reaction for detection of adenovirus after T cell-replete hematopoietic cell transplantation: viral load as a marker for invasive disease
    Veronique Erard
    Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109 1024, USA
    Clin Infect Dis 45:958-65. 2007
    ..The value of adenovirus plasma DNA detection as an indicator for adenovirus disease is unknown in the context of T cell-replete hematopoietic cell transplantation, of which adenovirus disease is an uncommon but serious complication...
  47. ncbi request reprint Infectious complications after autologous CD34-selected peripheral blood stem cell transplantation
    Fulvio Crippa
    Fred Hutchinson Cancer Research Center, Seattle Washington 98109 1024, USA
    Biol Blood Marrow Transplant 8:281-9. 2002
    ..Because the risk for infections approaches that seen in allogeneic transplant recipients, infection surveillance, diagnostic work-up, and prevention strategies similar to those used in allogeneic recipients are warranted...
  48. ncbi request reprint High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection
    W Garrett Nichols
    Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109 4417, USA
    J Infect Dis 185:273-82. 2002
    ..However, in D(+)/R(-) subjects, mortality appears to be associated with bacterial and fungal infection, indicating a possible immunomodulatory effect of primary CMV infection that was undetected despite intensive monitoring...
  49. ncbi request reprint Clinical outcomes of human herpesvirus 6 reactivation after hematopoietic stem cell transplantation
    Danielle M Zerr
    Department of Pediatrics, University of Washington, Seattle, Washington, USA
    Clin Infect Dis 40:932-40. 2005
    ..Although human herpesvirus 6 (HHV-6) is known to reactivate during hematopoietic stem cell transplantation (HSCT), the clinical significance of this finding is controversial...
  50. ncbi request reprint Adenovirus infection in hematopoietic stem cell transplantation: effect of ganciclovir and impact on survival
    Benedetto Bruno
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Biol Blood Marrow Transplant 9:341-52. 2003
    ..Ganciclovir, given for CMV prevention, may have a protective effect. Controlled treatment and prevention studies are warranted...
  51. ncbi request reprint Safety and tolerability of oseltamivir prophylaxis in hematopoietic stem cell transplant recipients: a retrospective case-control study
    Debie Vu
    Fred Hutchinson Cancer Research Center, Seattle, WA, 98109 1024, USA
    Clin Infect Dis 45:187-93. 2007
    ..However, no data exist regarding the use of oseltamivir as prophylaxis among patients undergoing hematopoietic stem cell transplantation (HSCT)...
  52. pmc Cytomegalovirus reactivation in critically ill immunocompetent patients
    Ajit P Limaye
    Department of Laboratory Medicine, University of Washington Medical Center, 1959 NE Pacific St, Seattle, WA 98195 7110, USA
    JAMA 300:413-22. 2008
    ....
  53. pmc Comparison of conventional and molecular detection of respiratory viruses in hematopoietic cell transplant recipients
    J Kuypers
    University of Washington, Seattle, Washington, USA
    Transpl Infect Dis 11:298-303. 2009
    ..To evaluate the relative sensitivity of respiratory virus detection in specimens from HCT recipients, we compared the results of conventional and quantitative molecular methods...
  54. pmc Timing and severity of community acquired respiratory virus infections after myeloablative versus non-myeloablative hematopoietic stem cell transplantation
    Joshua T Schiffer
    Fred Hutchinson Cancer Research Center, Seattle, WA 98102, USA
    Haematologica 94:1101-8. 2009
    ....
  55. ncbi request reprint Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients
    Fanny Li
    Department of Pharmacy Services, University of Washington, Seattle, WA 98195, USA
    Clin Infect Dis 45:439-47. 2007
    ..The incidence and clinical and virologic aspects of ganciclovir-resistant cytomegalovirus (CMV) disease have not been well-characterized in heart transplant recipients...
  56. pmc Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes
    Marco Mielcarek
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 113:2888-94. 2009
    ..We conclude that initial treatment with low-dose glucocorticoids for patients with grades I-II GVHD did not compromise disease control or mortality and was associated with decreased toxicity...
  57. pmc Pretransplant neutropenia is associated with poor-risk cytogenetic features and increased infection-related mortality in patients with myelodysplastic syndromes
    Bart L Scott
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 14:799-806. 2008
    ..94 [1.0-3.8], P = .05), but not for overall mortality or NRM. We propose that intensified strategies to prevent infections should be implemented in MDS patients with preexisting neutropenia who undergo HSCT...
  58. pmc Respiratory virus pneumonia after hematopoietic cell transplantation (HCT): associations between viral load in bronchoalveolar lavage samples, viral RNA detection in serum samples, and clinical outcomes of HCT
    Angela P Campbell
    Department of Pediatrics, University of Washington, Seattle, Washington, USA
    J Infect Dis 201:1404-13. 2010
    ..Few data exist on respiratory virus quantitation in lower respiratory samples and detection in serum from hematopoietic cell transplant (HCT) recipients with respiratory virus-associated pneumonia...
  59. ncbi request reprint Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants
    Kieren A Marr
    Program of Infectious Diseases, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Blood 103:1527-33. 2004
    ..69). There was no difference in overall or fungal-free survival. Itraconazole appears to prevent IMI in the subset of patients who tolerate the drug; however, toxicities and poor tolerability limit its success as prophylactic therapy...
  60. ncbi request reprint Immunologic recovery after hematopoietic cell transplantation with nonmyeloablative conditioning
    Michael Maris
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Exp Hematol 31:941-52. 2003
    ..We studied immune reconstitution in 51 recipients of HLA-identical hematopoietic cellular transplant (HCT) after nonmyeloablative conditioning compared to a reference group of 67 recipients after myeloablative conditioning...
  61. ncbi request reprint Immune evasion proteins of human cytomegalovirus do not prevent a diverse CD8+ cytotoxic T-cell response in natural infection
    Thomas J Manley
    Fred Hutchinson Cancer Research Center, D3 100, 1100 Fairview Ave N, Seattle, WA 98109, USA
    Blood 104:1075-82. 2004
    ..Thus, reconstitution of T-cell immunity in immunodeficient patients by cell therapy or by vaccination may need to target multiple viral antigens to completely restore immunologic control of CMV...
  62. ncbi request reprint Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products
    W Garrett Nichols
    Program in Infectious Diseases and Biostatistics, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 101:4195-200. 2003
    ..In an era of "universal leukoreduction," the abandonment of CMV-seronegative inventories appears premature, particularly among populations at high risk of CMV disease that do not receive active surveillance...
  63. ncbi request reprint Factors affecting antibody levels after allogeneic hematopoietic cell transplantation
    Jan Storek
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 101:3319-24. 2003
    ....
  64. ncbi request reprint Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors
    Kieren A Marr
    Fred Hutchinson Cancer Research Center Programs in Infectious Diseases and Long term Follow up, Seattle, WA 98109, USA
    Blood 100:4358-66. 2002
    ....
  65. ncbi request reprint Pretransplantation respiratory syncytial virus infection: impact of a strategy to delay transplantation
    Angela J Peck
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Clin Infect Dis 39:673-80. 2004
    ....
  66. ncbi request reprint Combination antifungal therapy for invasive aspergillosis
    Kieren A Marr
    Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Clin Infect Dis 39:797-802. 2004
    ..The results of in vitro studies and animal models suggest that combination therapy with azoles and echinocandins may have additive activity against Aspergillus species...
  67. ncbi request reprint Persistent fever in patients with neutropenia
    Lawrence Corey
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    N Engl J Med 346:222-4. 2002
  68. ncbi request reprint Impact of HLA A2 and cytomegalovirus serostatus on outcomes in patients with leukemia following matched-sibling myeloablative allogeneic hematopoietic cell transplantation
    Veronique Erard
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Haematologica 91:1377-83. 2006
    ..This study analyzed the role of donor CMV serostatus and HLA-A2 status on leukemia outcomes in a large population of HLA-identical HCT recipients...
  69. ncbi request reprint Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen
    H Joachim Deeg
    Fred Hutchinson Cancer Research Center and University of Washington School of Medicine, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 12:573-84. 2006
    ....
  70. ncbi request reprint High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy
    Ajit P Limaye
    Department of Laboratory Medicine, University of Washington, Seattle, WA, USA
    J Infect Dis 185:20-7. 2002
    ..All ganR isolates contained a UL97 mutation. GanR CMV infection occurs in nearly 10% of lung transplant recipients, despite preemptive antiviral therapy, and is more common among D+/R- patients...
  71. ncbi request reprint Unrelated donor status and high donor age independently affect immunologic recovery after nonmyeloablative conditioning
    Frederic Baron
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 6072, USA
    Biol Blood Marrow Transplant 12:1176-87. 2006
    ..Other factors significantly associated with delayed immune recovery were advanced donor age, low numbers of CD34 and T cells in the graft, and development of graft-versus-host disease...
  72. ncbi request reprint Transferred herpes simplex virus immunity after stem-cell transplantation: clinical implications
    W Garrett Nichols
    Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, University of Washington, 1100 Fairview Avenue N, D3 100, Seattle, WA 98109 4417, USA
    J Infect Dis 187:801-8. 2003
    ..Serological testing of donors can identify patients who are at highest risk for HSV-related morbidity, for whom prolonged prophylaxis or donor vaccination (once available) could be considered...
  73. ncbi request reprint Cyclophosphamide metabolism is affected by azole antifungals
    Kieren A Marr
    Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D3 100, Seattle, WA 98109, USA
    Blood 103:1557-9. 2004
    ..These data suggest that azole antifungals, through differential inhibition of hepatic cytochrome P-450 isoenzymes, affect CY metabolism and conditioning-related toxicities...
  74. ncbi request reprint Prolonged outbreak of human parainfluenza virus 3 infection in a stem cell transplant outpatient department: insights from molecular epidemiologic analysis
    W Garrett Nichols
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 4417, USA
    Biol Blood Marrow Transplant 10:58-64. 2004
    ..The concept of nosocomial transmission should be expanded to include the OPD for immunosuppressed patients...
  75. doi request reprint DAS181 treatment of severe parainfluenza type 3 pneumonia in a lung transplant recipient
    D R Drozd
    Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington 98195 6175, USA
    Transpl Infect Dis 15:E28-32. 2013
    ..Treatment was well tolerated and associated with improvement in oxygenation and symptoms, along with rapid clearance of PIV. DAS181 should be systematically evaluated for treatment of PIV infection in transplant recipients...
  76. ncbi request reprint Efficacy of donor vaccination before hematopoietic cell transplantation and recipient vaccination both before and early after transplantation
    J Storek
    Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA 98109 1024, USA
    Bone Marrow Transplant 33:337-46. 2004
    ..In contrast, neither recipient immunization on days -1 and 50 nor donor immunization on day -20 appears to be efficacious for polysaccharide antigens and poorly immunogenic protein neo-antigens...
  77. pmc How I treat influenza in patients with hematologic malignancies
    Corey Casper
    Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 115:1331-42. 2010
    ..We also summarize infection control and vaccination strategies for patients, family members, and caregivers...
  78. ncbi request reprint BK virus infection in hematopoietic stem cell transplant recipients: frequency, risk factors, and association with postengraftment hemorrhagic cystitis
    Veronique Erard
    Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Clin Infect Dis 39:1861-5. 2004
    ..7x10(3) vs. 0 copies/mL; P=.0006). BK viremia also was strongly associated with postengraftment hemorrhagic cystitis in a time-dependent analysis (P=.004)...
  79. ncbi request reprint Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy
    W Garrett Nichols
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 4417, USA
    Clin Infect Dis 39:1300-6. 2004
    ..Risk factors for acquisition, progression to pneumonia, and the effect of antiviral therapy are unknown...
  80. ncbi request reprint Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center
    Takahiro Fukuda
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 10:494-503. 2004
    ....
  81. doi request reprint An outbreak of varicella with likely breakthrough disease in a population of pediatric cancer patients
    Amanda L Adler
    Department of Pediatrics, University of Washington, Children s Hospital and Regional Medical Center, Seattle, Washington 98105, USA
    Infect Control Hosp Epidemiol 29:866-70. 2008
    ..We describe an outbreak of varicella with likely breakthrough disease in a population of pediatric cancer patients in October 2004...
  82. pmc Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation
    Pierre Yves Bochud
    Institute for Systems Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    N Engl J Med 359:1766-77. 2008
    ..We examined the role of TLR polymorphisms in conferring a risk of invasive aspergillosis among recipients of allogeneic hematopoietic-cell transplants...
  83. ncbi request reprint Invasive Pseudomonas aeruginosa infections: high rate of recurrence and mortality after hematopoietic cell transplantation
    M Hakki
    Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Bone Marrow Transplant 39:687-93. 2007
    ..aeruginosa infections are associated with high recurrence rates and mortality in this immunocompromised population. Aggressive attempts to reduce immunosuppression and to treat copathogens may help during the initial infection...
  84. ncbi request reprint Incidence, risk factors, and mortality from pneumonia developing late after hematopoietic stem cell transplantation
    Chien Shing Chen
    Clinical Research Division, Fred Hutchinson Cancer Research Center and the University of Washington, School of Medicine Seattle, WA, USA
    Bone Marrow Transplant 32:515-22. 2003
    ..5, P=0.007). Our data suggest that extension of PCP prophylaxis may be beneficial in high-risk autograft recipients. Further study of long-term anti-infective prophylaxis based on patient risk factors after SCT appear warranted...
  85. ncbi request reprint Independent contribution of bronchoalveolar lavage and serum galactomannan in the diagnosis of invasive pulmonary aspergillosis
    C E Fisher
    Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA
    Transpl Infect Dis 16:505-10. 2014
    ..BAL GMI sensitivity was not affected by receipt of mold-active therapy in our cohort. ..
  86. ncbi request reprint Adenovirus nephritis in hematopoietic stem-cell transplantation
    Benedetto Bruno
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 4417, USA
    Transplantation 77:1049-57. 2004
    ..Although adenovirus (ADV) infections may involve many different organs, kidney infection is seldom reported in association with hematopoietic stem-cell transplantation (HSCT)...
  87. pmc Lipopolysaccharide binding protein promoter variants influence the risk for Gram-negative bacteremia and mortality after allogeneic hematopoietic cell transplantation
    Jason W Chien
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 111:2462-9. 2008
    ..83; 95% CI, 1.38-16.75, P = .013). These data suggest that transcriptional regulation of the LBP gene contributes to the risk for developing GN bacteremia and death after HCT...
  88. ncbi request reprint Specific delineation of BK polyomavirus in kidney tissue with a digoxigenin-labeled DNA probe
    Rachael K Parkin
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, P O Box 19024 1100, Fairview Ave N D2 190, Seattle, WA 98109 1024, USA
    Mol Cell Probes 19:87-92. 2005
    ..Alternatively, high stringency hybridization conditions may be utilized, detecting BKV only. BK associated tubular necrosis is clearly demonstrated in two cases of BK nephritis...

Research Grants3

  1. Respiratory Viruses and Airflow Obstruction after HCT
    Michael Boeckh; Fiscal Year: 2006
    ..These studies will improve our understanding of the interaction between respiratory viruses and late pulmonary complications after HCT, which will ultimately enable us to formulate more rational treatment strategies. ..
  2. Respiratory Viruses and Airflow Obstruction after HCT
    Michael Boeckh; Fiscal Year: 2007
    ..These studies will improve our understanding of the interaction between respiratory viruses and late pulmonary complications after HCT, which will ultimately enable us to formulate more rational treatment strategies. ..